Journal Mobile Options
Table of Contents
Vol. 25, No. 2, 2005
Issue release date: March–April 2005
Am J Nephrol 2005;25:106–115

Carnitine Therapy Is Associated with Decreased Hospital Utilization among Hemodialysis Patients

Kazmi W.H. · Obrador G.T. · Sternberg M. · Lindberg J. · Schreiber B. · Lewis V. · Pereira B.J.G.
aDivision of Nephrology, Tufts-New England Medical Center, Boston, Mass.; bQuartiles Statistical Consulting, LLC, Atlanta, Ga.; cOchsner Hemodialysis Research Program, New Orleans, La.; dDepartment of Medicine, Medical College of Wisconsin, Milwaukee, Wisc., and eTulane University School of Public Health and Tropical Medicine, New Orleans, La., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Hospitalizations account for 41% of the total cost of end-stage renal disease (ESRD) care. Carnitine deficiency is common among dialysis patients, and some studies have shown improvements in anemia, and cardiac and skeletal muscle function upon administration of L-carnitine. We hypothesized that L-carnitine may be associated with decreased hospital utilization in these patients. Methods: The Fresenius Medical Care North America dialysis database was used for this retrospective analysis. Adult patients who received carnitine for at least 3 months, and had at least 3 months of pre-carnitine follow-up were included in the study. Hospitalization and hospital day rates were compared before and during carnitine therapy, and with a matched population. Results: Carnitine therapy at a mean dose of 1.5 ± 0.7 g per administration for an average of 9.7 ± 5.4 months was associated with a significant reduction in hospital utilization. Patients with cardiovascular disease, defined as hospitalizations for angina, myocardial infarction, arrhythmia, congestive heart failure, cerebral vascular disease or peripheral vascular disease prior to receiving carnitine, and those with anemia and hypoalbuminemia derived the greatest benefit from carnitine therapy. In a multivariate analysis, compared to 3 months prior to the initiation of carnitine, the adjusted relative risk for hospitalization was 11, 11, and 15% lower at 3, 6, and 9 months, respectively. Among patients with cardiovascular disease, the reduction in risk was even more significant (24, 31, and 34% lower at 3, 6, and 9 months, respectively). Similar results were observed with adjusted relative risk for hospital days. Conclusion: Administration of L-carnitine to chronic hemodialysis patients is associated with lower hospital utilization.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
  2. Popovic J, Kozak L: National hospital discharge survey: Annual summary, 1998. National Center for Health Statistics. Vital Health Stat 2000;3:1–194.
  3. USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2001.
  4. Bruns F, Seddon P, Saul M, Zeidel ML: The cost of caring for end-stage renal disease patients: An analysis based on hospital financial transaction records. J Am Soc Nephrol 1998;9:884–890.
  5. Arora P, Kausz A, Obrador G, Ruthanzer R, Khan S, Jenuleson C, Meyer K, Pereira B: Hospital utilization among chronic dialysis patients. J Am Soc Nephrol 2000;11:740–746.
  6. Bohmer T, Rydning A, Solberg H: Carnitine levels in human serum in health and disease. Clin Chim Acta 1974;57:55–61.
  7. Bohmer T, Bergrem H, Eiklid K: Carnitine deficiency induced during intermittent hemodialysis for renal failure. Lancet 1978;i:126–128.
  8. Bremer J: Carnitine-metabolism and functions. Physiol Rev 1983;63:1420–1480.
  9. Rebouche C, Paulson D: Carnitine metabolism and function in humans. Annu Rev Nutr 1986;6:41–66.
  10. Van der Vusse G, Glatz J, Stam H, Reneman R: Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992;72:881–940.
  11. Goral S: Levocarnitine’s role in the treatment of patients with end-stage renal disease: A review. Dial Transplant 2001;30:530–538.

    External Resources

  12. Rizos I: Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000;139:S120–S123.

    External Resources

  13. Ilceto S, Scrutinio D, Bruzzi P, Ambrosio D, Boni L, Di Biase M, Rizzon P: Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardica (CEDIM) Trial. J Am Coll Cardiol 1995;26:380–387.
  14. Romagnoli G, Naso A, Carraro G, Lidestri V: Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: an observational study. Curr Med Res Opin 2002;18:172–175.
  15. Maeda K, Shinzato T, Kobayakawa H: Effects of L-carnitine on short-chain fatty acid (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 1989;51:355–361.
  16. Kooistra M, Struyvenberg A, van Es A: The response to recombinant human erythropoietin in patients with anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991;57:127–128.
  17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61.
  18. Van Es A, Henny F, Kooistra M, Lobatto S, Scholte H: Amelioration of cardiac function by L-carnitine administration in patients on hemodialysis. Contrib Nephrol. Basel, Karger, 1992, vol 98, pp 28–35.
  19. Thamer M, Ray NF, Fehrenbach SN, Richard C, Kimmel PL: Relative risk and economic consequences of inpatient care among patients with renal failure. J Am Soc Nephrol 1996;7:751–762.
  20. Rocco MV, Soucie MJ, Reboussin DM, McClellan WM: Risk factors for hospital utilization in chronic dialysis patients. J Am Soc Nephrol 1996;7:889–896.
  21. Hurot JM, Cucherat M, Haugh M, Fouque D: Effects of L-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J Am Soc Nephrol 2002;13:708–714.
  22. Ahmad S, Robertson H, Golper T, Kurtin P, Katz L, Kopple J: Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990;38:912–918.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50